Cite
HARVARD Citation
Hodi, F. et al. (n.d.). 23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). European journal of cancer. pp. S721-. [Online].